TY - JOUR
T1 - Cost Impact of Bevacizumab and Cetuximab Associated Therapies in Colorectal Cancer in Veneto Region
AU - Ballali, Simonetta
AU - Chiffi, Daniele
AU - Trojniak, Marta P.
AU - Gregori, Dario
AU - Grigoletto, Francesco
AU - Perissinotto, Egle
AU - Buja, Alessandra
AU - Tramarina, Andrea
AU - Gallo, Costantino
AU - Compostella, Antonio
AU - Pastorelli, Davide
AU - Rausa, Giuseppe
PY - 2013
Y1 - 2013
N2 - Objective: To assess the economic impact of the introduction of bevacizumab and cetuximab, in 1st and 2nd line treatment of mCRC patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of bevacizumab and cetuximab use in patients with mCRC for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no-treatment groups, along the lines of previously published studies. Results: The cost impact of bevacizumab administration in patients with mCRC accounted a mean value of 18268788 € within the first 6 months. Cetuximab therapy for those refractory to 1st line treatment, increased costs of almost 833340 € in the first 6 months, increasing in the following period due to a higher portion of patients switching from a stable status to a progressive one. Discussion: The cost impact of monoclonal antibodies on health expenses is very high. For a regional cohort like the Veneto's one, figure sets around 19000000 € in 6 months, when considering 1st and 2nd line treatment, reaching the level of 50000000 € within three years.
AB - Objective: To assess the economic impact of the introduction of bevacizumab and cetuximab, in 1st and 2nd line treatment of mCRC patients in Veneto region (North-East of Italy). Methods: A Markov state decision model was implemented to evaluate the cost impact of bevacizumab and cetuximab use in patients with mCRC for a lapse of time of three years in Veneto public hospitals. The Markov model expressed transition probabilities from three different states, comparing in addition the expected deaths and the monthly survival rates in treatment and no-treatment groups, along the lines of previously published studies. Results: The cost impact of bevacizumab administration in patients with mCRC accounted a mean value of 18268788 € within the first 6 months. Cetuximab therapy for those refractory to 1st line treatment, increased costs of almost 833340 € in the first 6 months, increasing in the following period due to a higher portion of patients switching from a stable status to a progressive one. Discussion: The cost impact of monoclonal antibodies on health expenses is very high. For a regional cohort like the Veneto's one, figure sets around 19000000 € in 6 months, when considering 1st and 2nd line treatment, reaching the level of 50000000 € within three years.
KW - Bevacizumab
KW - Cetuximab
KW - Cost
KW - KRAS wild type
KW - Metastatic colorectal cancer
KW - Veneto
UR - http://www.scopus.com/inward/record.url?scp=84879130178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879130178&partnerID=8YFLogxK
U2 - 10.2174/1874143601307010009
DO - 10.2174/1874143601307010009
M3 - Article
AN - SCOPUS:84879130178
VL - 7
SP - 9
EP - 16
JO - Open Pharmacology Journal
JF - Open Pharmacology Journal
SN - 1874-1436
IS - SPEC ISS 1
ER -